Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: A critical review

Current Topics in Medicinal Chemistry

Volumn 12, Issue 21, 2012, Pages 2357-2374

  Masana, Mercè ^a,b,c   Santana, Noemí ^a,b   Artigas, Francesc ^a,b   Bortolozzi, Analía ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antipsychotic drugs; Cognitive deficits; Monoamines; Prefrontal cortex; Schizophrenia

Indexed keywords

3 (1 ADAMANTYL) 1 AMINOMETHYL 3, 4 DIHYDRO 5, 6 DIHYDROXY 1H 2 BENZOPYRAN; 3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 5 (2, 3 DIHYDROBENZOFURAN 7 YL) 2, 3, 4, 5 TETRAHYDRO 3 METHYL 8 NITRO 1H 3 BENZAZEPIN 7 OL; 6 CHLORO 2, 3, 4, 5 TETRAHYDRO 7, 8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 7 CHLORO 2 [[1 (2 METHOXYPHENYL) 4 PIPERIDYL] METHYLAMINOMETHYL] 1, 4 BENZODIOXAN; 7 CHLORO 2 [[1 (2 METHOXYPHENYL) 4 PIPERIDYL]METHYLAMINOMETHYL] 1,4 BENZODIOXAN; 8 CHLORO 2, 3, 4, 5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADOPRAZINE; ALPHA [1 [2 (1, 4 BENZODIOXAN 5 YLOXY) ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BREXPIPRAZOLE; CARIPRAZINE; CLONIDINE; CLOZAPINE; DIHYDREXIDINE; DOPAMINE; ECOPIPAM; GUANFACINE; HALOPERIDOL; N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; N [4 [2 (6 CYANO 1, 2, 3, 4 TETRAHYDRO 2 ISOQUINOLINYL) ETHYL] CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NNC 010687; N[4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; OLANZAPINE; PRAMIPEXOLE; PRECLAMOL; RISPERIDONE; ROXINDOLE; SONEPIPRAZOLE; TALIPEXOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN; ZIPRASIDONE;

ALERTNESS; ALZHEIMER DISEASE; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; FUNCTIONAL NEUROIMAGING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEARNING; LOW DRUG DOSE; MICROPHOTOGRAPHY; MONOAMINERGIC SYSTEM; NEUROTRANSMISSION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROBLEM SOLVING; SCHIZOPHRENIA; SINGLE DRUG DOSE; WORKING MEMORY;

EID: 84874887231     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805289872     Document Type: Article

References (261)

1. Miyamoto, S.; Duncan, G.E.; Marx, C.E.; Lieberman, J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry, 2005, 10, 79-104.
2. Miyamoto, S.; Miyake, N.; Jarkog, L.F.; Fleischhacker, W.W.; Lieberman, J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effetcs of current and future therapeutic agents. Mol. Psychiatry, 2012, doi: 10.1038/mp.2012.47. [Epub ahead of print].
3. Jarskog, L.F.; Miyamoto, S.; Lieberman, J.A. Schizophrenia: new pathological insights and therapies. Annu. Rev. Med., 2007, 58, 4961.
4. Biedermann, F.; Fleischhacker, W.W. Emerging drugs for schizo phrenia. Expert. Opin. Emerg. Drugs, 2011, 16, 271-282.
5. Carlsson, A. Antipsychotic drugs, neurotransmitters, and schizo phrenia. Am. J. Psychiatry, 1978, 135, 165-173.
6. Weinberger, D.R.; Berman, K.F.; Chase, T.N. Mesocortical dopa-minergic function and human cognition. Ann. NY. Acad. Sci., 1988, 537, 330-338.
7. Abi-Dargham, A.; Rodenhiser, J.; Printz, D.; Zea-Ponce, Y.; Gil, R.; Kegeles, L.S.; Weiss, R.; Cooper, T.B.; Mann, J.J.; Van Heertum, R.L.; Gorman, J.M.; Laruelle, M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA, 2000, 97, 8104-8109.
8. Lewis, D.A.; Lieberman, J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron, 2000, 28, 325-334.
9. Abi-Dargham, A.; Laruelle, M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry, 2005, 20, 15-27.
10. Conn, P.J.; Tamminga, C.; Schoepp, D.D.; Lindsley, C. Schizophrenia: moving beyond monoamine antagonists. Mol. Interv., 2008, 8, 99-107.
11. Leucht, S.; Corves, C.; Arbter, D.; Engel, R.R.; Li, C.; Davis, J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009, 373, 31-41.
12. Artaloytia, J.F.; Arango, C.; Lahti, A.; Sanz, J.; Pascual, A.; Cubero, P.; Prieto, D.; Palomo, T. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am. J. Psychiatry, 2006, 163, 488-93.
13. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry., 1988, 45, 789-96.
14. Meltzer, H.Y.; McGurk, S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 1999, 25, 233-255.
15. Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353, 1209-1223.
16. Meltzer, H.Y.; Matsubara, S.; Lee, J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther., 1989, 251, 238-246.
17. Remington, G.; Kapur, S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl.), 2000, 148, 315.
18. Farde, L.; Wiesel, F. A.; Nordstrom, A. L.; Sedvall, G. D1and D2-Dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl.), 1989, 99, S28-S31.
19. Kapur, S.; Zipursky, R.B.; Remington, G. Clinical and theorical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry, 1999, 156, 286-293.
20. Kapur, S.; Zipursky, R.; Jones, C.; Remington, G.; Houle, S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry, 2000, 157, 514-520.
21. Kapur, S.; Seeman, P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?. A new hypothesis. Am. J. Psychiatry, 2001, 158, 360-369.
22. Inoue, T.; Domae, M.; Yamada, K.; Furukawa, T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1 piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther., 1996, 277, 137-143.
23. Burris, K.D.; Molski, T.F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F.D.; Molinoff, P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther., 2002, 302, 381-389.
24. Jordan, S.; Koprivica, V.; Chen, R.; Tottori, K.; Kikuchi, T.; Altar, C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol., 2002, 441, 137-140.
25. Shapiro, D.A.; Renock, S.; Arrington, E.; Chiodo, L.A.; Liu, L.X.; Sibley, D.R.; Roth, B.L.; Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 2003, 28, 1400-1411.
26. Roth, B.L.; Sheffler, D.L.; Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov., 2004, 3, 353-359.
27. Miyamoto, S.; Duncan, G.E.; Goff, D.C.; Lieberman, J.A. Therapeutics of schizophrenia. In: Neuropsychopharmacology: The Fifth Generation of Progress; Davis, K.L.; Charney, D.; Coyle, J.T., Nemeroff, C., Eds; Lippincott Williams & Wilkins: Philadelphia, 2002, pp. 775-807.
28. Elvevåg, B.; Goldberg, T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol., 2000, 14, 121.
29. Green, M.F.; Kern, R.S.; Braff, D.L.; Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'?. Schizophr. Bull., 2000, 26, 119-136.
30. Kerns, J.G.; Berenbaum, H. Cognitive impairments associated with formal thought disorder in people with schizophrenia. J. Abnorm. Psychol., 2002, 111, 211-224.
31. Green, M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry., 1996, 153, 321330.
32. Weinberger, D.R.; Gallhofer, B. Cognitive function in schizophrenia. Int. Clin. Psychopharmacol., 1997, 12(Suppl 4), S29-S36.
33. Harvey, P.D.; Keefe, R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry, 2001, 158, 176-184.
34. Hagan, J.J.; Jones, D.N. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull., 2005, 31, 830-853.
35. Gray, J.A.; Roth, B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull., 2007, 33, 11001119.
36. Keefe, R.S. Cognitive deficits in patients with schizophrenia: effects and treatment. J. Clin. Psychiatry, 2007, 68, 8-13.
37. Fuster, J.M. The prefrontal cortex. Anatomy, physiology and neuropsychology of the frontal lobe; Lipincott-Raven: PhiladelphiaNew York, 1997.
38. Fuster, J.M. The prefrontal cortex An update: Time is of the essence. Neuron, 2001, 30, 319-333.
39. Miller, E.K. The prefrontal cortex and cognitive control. Nat. Rev. Neurosci., 2000, 1, 59-65.
40. Miller, E.K.; Cohen, J.D. An integrative theory of prefrontal cortex function. Annu. Rev. of Neurosci, 2001, 24, 167-202.
41. Dove, A.; Pollmann, S.; Schubert, T.; Wiggins, C.J.; von Cramon, D.Y. Prefrontal cortex activation in task switching: an eventrelated fMRI study. Brain Res. Cogn. Brain Res., 2000, 9, 103-109.
42. Brass, M.; von Cramon, D.Y. The role of the frontal cortex in task preparation. Cereb. Cortex, 2002, 12, 908-914.
43. Braver, T.S.; Reynolds, J.R.; Donaldson, D.I. Neural mechanisms of transient and sustained cognitive control during task switching. Neuron, 2003, 39, 713-726.
44. Liston, C.; Matalon, S.; Hare, T.A.; Davidson, M.C.; Casey, B.J. Anterior cingulated and posterior parietal cortices are sensitive to dissociable forms of conflict in a task-switching paradigm. Neuron, 2006, 50, 643-653.
45. Goldman-Rakic, P.S. Development of cortical circuitry and cognitive function. Child. Dev., 1987, 58, 601-622.
46. Fuster, J.M. Behavioral electrophysiology of the prefrontal cortex of the primate. Prog. Brain Res., 1990, 85, 313-323.
47. Funahashi, S.; Inoue, M.; Kubota, K. Delay-related activity in the primate prefrontal cortex during sequential reaching tasks with delay. Neurosci. Res., 1993, 18, 171-175.
48. Hajós, M.; Richards, C.D.; Szekely, A.D.; Sharp, T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience, 1998, 87, 95-108.
49. Jodo, E.; Chiang, C.; Aston-Jones, G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience, 1998, 83, 63-79.
50. Carr, D.B.; Sesack, S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J. Neurosci., 2000, 20, 3864-3873.
51. Celada, P.; Puig, M.V.; Casanovas, J.M.; Guillazo, G.; Artigas, F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A) and glutamate receptors. J. Neurosci., 2001, 21, 9917-9929.
52. Williams, G.V.; Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 1995, 376, 572-575.
53. Gao, W.J.; Wang, Y.; Goldman-Rakic, P.S. Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J. Neurosci., 2003, 23, 1622-1630.
54. Wang, Y.; Goldman-Rakic, P.S. D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons. Proc. Natl. Acad. Sci. USA, 2004, 101, 5093-5098.
55. Puig, M.V.; Artigas, F.; Celada, P. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb. Cortex, 2005, 15, 1-14.
56. Puig, M.V.; Gulledge, A.T. Serotonin and prefrontal cortex function: neurons, networks, and circuits. Mol. Neurobiol., 2011, 44, 449-464.
57. Gao, W.J.; Goldman-Rakic, P.S. Selective modulation of excitatory and inhibitory microcircuits by dopamine. Proc. Natl. Acad. Sci. USA, 2003, 100, 2836-2841.
58. Graybiel, A.M.; Aosaki, T.; Flaherty, A.W.; Kimura, M. The basal ganglia and adaptive motor control. Science, 1994, 265, 18261831.
59. W. Predictive reward signal of dopamine neurons. J. Neurophysiol., 1998, 80, 1-27.
60. Koob, G.F.; Le Moal, M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 2001, 24, 97-129.
61. Dalley, J.W.; Cardinal, R.N.; Robbins, T.W. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci. Biobehav. Rev., 2004, 28, 771-784.
62. Grace, A.A.; Floresco, S.B.; Goto, Y.; Lodge, D.J. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci., 2007, 30, 220-227.
63. Iversen, S.D.; Iversen, L.L. Dopamine: 50 years in perspective. Trends Neurosci., 2007, 30, 188-193.
64. Williams, G.V.; Castner, S.A. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience, 2006, 139, 263-276.
65. Vijayraghavan, S.; Wang, M.; Birnbaum, S.G.; Williams, G.V.; Arnsten, A.F. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci., 2007, 10, 376-384.
66. Moghaddam, B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol. Psychiatry, 2002, 51, 775-787.
67. P.J. The neuropathology of schizophrenia A critical review of the data and their interpretation. Brain, 1999, 122, 593-624.
68. Selemon, L.D.; Goldman-Rakic, P.S. The reduced neuropil hypothesis: A circuit based model of schizophrenia. Biol. Psychiatry, 1999, 45, 17-25.
69. Okubo, Y.; Suhara, T.; Suzuki, K.; Kobayashi, K.; Inoue, O.; Terasaki, O.; Someya, Y.; Sassa, T.; Sudo, Y.; Matsushima, E.; Iyo, M.; Tateno, Y.; Toru, M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 1997, 385, 634-636.
70. Laruelle, M.; Kegeles, L.S.; Abi-Dargham, A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. NY. Acad. Sci., 2003, 1003, 138-158.
71. Carlsson, M.L.; Carlsson, A.; Nilsson, M. Schizophrenia: from dopamine to glutamate and back. Curr. Med. Chem., 2004, 11, 267-277.
72. Lewis, D.A.; Hashimoto, T.; Volk, D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci., 2005, 6, 312-324.
73. Andreasen, N.C.; O'Leary, D.S.; Flaum, M.; Nopoulos, P.; Watkins, G.L.; Boles Ponto, L.L.; Hichwa, R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neurolepticnaïve patients. Lancet, 1997, 349, 1730-1734.
74. Potkin, S.G.; Alva, G.; Fleming, K.; Anand, R.; Keator, D.; Carreon, D.; Doo, M.; Jin, Y.; Wu, J.C.; Fallon, J.H. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am. J. Psychiatry, 2002, 159, 227-37.
75. Dierks, T.; Linden, D.E.; Jandl, M.; Formisano, E.; Goebel, R.; Lanfermann, H.; Singer, W. Activation of Heschl's gyrus during auditory hallucinations. Neuron, 1999, 22, 615-621.
76. Shergill, S.S.; Brammer, M.J.; Williams, S.C.; Murray, R.M.; Mcguire, P.K. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch. Gen. Psychiatry, 2000, 57, 1033-1038.
77. S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry, 2003, 160, 13-23.
78. González-Maeso, J.; Sealfon, S.C. Psychedelics and schizophrenia. Trends Neurosci., 2009, 32, 225-232.
79. McGuire, P.; Howes, O.D.; Stone, J.; Fusar-Poli, P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol. Sci., 2008, 29, 91-98.
80. Minzenberg, M. J.; Laird, A.R.; Thelen, S.; Carter, C.S.; Glahn, D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry, 2009; 66, 811-822.
81. Barnett, J.H.; Robbins, T.W.; Leeson, V.C.; Sahakian, B.J.; Joyce, E.M.; Blackwell, A.D. Assessing cognitive function in clinical trials of schizophrenia. Neurosci. Biobehav. Rev., 2010, 34, 11611177.
82. Pettersson-Yeo, W.; Allen, P.; Benetti, S.; McGuire, P.; Mechelli, A. Dysconnectivity in schizophrenia: where are we now? Neurosci. Biobehav. Rev., 2011, 35, 1110-1124.
83. Minzenberg, M. J.; Laird, A.R.; Thelen, S.; Carter, C.S.; Glahn, D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry, 2009, 66, 811-822.
84. Pettersson-Yeo, W.; Allen, P.; Benetti, S.; McGuire, P.; Mechelli, A. Dysconnectivity in schizophrenia: where are we now?. Neurosci. Biobehav. Rev., 2011, 35, 1110-1124.
85. Millan, M.J.; Agid, Y.; Brüne, M.; Bullmore, E.T.; Carter, C.S.; Clayton, N.S.; Connor, R.; Davis, S.; Deakin, B.; DeRubeis, R.J.; Dubois, B.; Geyer, M.A.; Goodwin, G.M.; Gorwood, P.; Jay, T.M.; Joëls, M.; Mansuy, I.M.; Meyer-Lindenberg, A.; Murphy, D.; Rolls, E.; Saletu, B.; Spedding, M.; Sweeney, J.; Whittington, M.; Young, L.J. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov., 2012, 11, 141-168.
86. Broome, M.R.; Matthiasson, P.; Fusar-Poli, P.; Woolley, J.B.; Johns, L.C.; Tabraham, P.; Bramon, E.; Valmaggia, L.; Williams, S.C.; Brammer, M.J.; Chitnis, X.; McGuire, P.K. Neural correlates of executive function and working memory in the 'at-risk mental state'. Br. J. Psychiatry, 2009, 194, 25-33.
87. Fusar-Poli, P.; Howes, O.D.; Allen, P.; Broome, M.; Valli, I.; Asselin, M.C.; Grasby, P.M.; McGuire, P.K. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatry, 2010, 67, 683-691.
88. Li, X.; Branch, C.A.; DeLisi, L.E. Language pathway abnormalities in schizophrenia: a review of fMRI and other imaging studies. Curr. Opin. Psychiatry, 2009, 22, 131-139.
89. Tamminga, C.A.; Thaker, G.K.; Buchanan, R.; Kirkpatrick, B.; Alphs, L.D.; Chase, T.N.; Carpenter, W.T. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry, 1992, 49, 522-530.
90. Lewis, D.A.; Cruz, D.A.; Melchitzky, D.S.; Pierri, J.N. Laminaspecific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am. J. Psychiatry, 2001, 158, 1411-1422.
91. Allen, P.; Seal, M.L., Valli, I.; Fusar-Poli, P.; Perlini, C.; Day, D.; Wood, S.J.; Williams, S.C.; McGuire, P.K. Altered prefrontal and hippocampal function during verbal encoding and recognition in people with prodromal symptoms of psychosis. Schizophr Bull., 2011, 37, 746-756.
92. Broyd, S.J.; Demanuele, C.; Debener, S.; Helps, S.K.; James, C.J.; Sonuga-Barke, E.J. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci. Biobehav. Rev., 2009, 33, 279-296.
93. McGuire, P.; Howes, O.D.; Stone, J.; Fusar-Poli, P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol. Sci., 2008, 29, 91-98.
94. Fusar-Poli, P.; Deste, G.; Smieskova, R.; Barlati, S.; Yung, A.R.; Howes, O.; Stieglitz, R.D.; Vita, A.; McGuire, P.; Borgwardt, S. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch. Gen. Psychiatry, 2012, 69, 562-571.
95. Olabi, B.; Ellison-Wright, I.; Bullmore, E.; Lawrie, S.M. Structural brain changes in first episode Schizophrenia compared with Fronto-Temporal Lobar Degeneration: a meta-analysis. BMC Psychiatry, 2012, 7, 12:104, doi: 10.1186/1471-244X-12-104.
96. Smieskova, R.; Allen, P.; Simon, A.; Aston, J.; Bendfeldt, K.; Drewe, J.; Gruber, K.; Gschwandtner, U.; Klarhoefer, M.; Lenz, C.; Scheffler, K.; Stieglitz, R.D.; Radue, E.W.; McGuire, P.; Riecher-Rösslerm A.; Borgwardt, S.J. Different duration of at-risk mental state associated with neurofunctional abnormalities. A multimodal imaging study. Hum. Brain Mapp., 2012, 33, 2281-2294.
97. Williamson, P.C.; Allman, J.M. A framework for interpreting functional networks in schizophrenia. Front. Hum. Neurosci., 2012, 6:184. Epub 2012 Jun 21.
98. Roberts, A.C.; De Salvia, M.A.; Wilkinson, L.S.; Collins, P.; Muir, J.L.; Everitt, B.J.; Robbins, T.W. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J. Neurosci., 1994, 14, 2531-2544.
99. Robbins, T.W. From arousal to cognition: the integrative position of the prefrontal cortex. Prog. Brain Res., 2000, 126, 469-483.
100. Winstanley, C.A.; Chudasama, Y.; Dalley, J.W.; Theobald, D.E.; Glennon, J.C.; Robbins, T.W. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacol., 2003, 167, 304-314.
101. Carli, M.; Baviera, M.; Invernizzi, R.W.; Balducci, C. Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacol., 2006, 31, 757-767.
102. Ramos, B.P.; Arnsten, A.F. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol. Ther., 2007, 113, 523-536.
103. Thierry, A.M.; Godbout, R.; Mantz, J.; Glowinski, J. Influence of the ascending monoaminergic systems on the activity of the rat prefrontal cortex. Prog. Brain Res., 1990, 85, 357-364.
104. Grace, A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 1991, 41, 1-24.
105. O'Donnell, P. Dopamine gating of forebrain neural ensembles. Eur. J. Neurosci., 2003, 17, 429-435.
106. Seamans, J.K.; Yang, C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol., 2004, 74, 1-58.
107. Lapish, C.C.; Kroener, S.; Durstewitz, D.; Lavin, A.; Seamans, J.K. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacol. (Berl), 2007, 191, 609-625.
108. Santana, N; Mengod, G.; Artigas, F. Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cerebral Cortex, 2009,19, 849-860.
109. McCune, S.K.; Voigt, M.M.; Hill, J.M. Expression of multiple alpha adrenergic receptor subtype messenger RNAs in the adult rat brain. Neuroscience, 1993, 57,143-151.
110. Pieribone, V.A.; Nicholas, A.P.; Dagerlind, A.; Hökfelt, T. Distribution of alpha1 adrenoceptors in rat brain revealed by in situ hybridization experiments utilizing subtype-specific probes. J. Neurosci., 1994, 14, 4252-4268.
111. Day, H.E.; Campeau, S.; Watson, S.J.; Akil, H. Distribution of alpha-1A, alpha-1B and alpha-1D-adrenergic receptor mRNA in the rat brain and spinal cord. J. Chem. Neuroanat., 1997, 13, 115-139.
112. Santana, N; Mengod, G.; Artigas, F. Expression of alpha1adrenergic receptors in rat prefrontal cortex: HYPERLINK"/ pubmed/23195622" Expression of oi1 -adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT2A receptors. Int J Neuropsychopharmacol. 2012 [Epub ahead of print]
113. Marek, G.J.; Aghajanian, G.K. 5-HT2A receptor or alpha1adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur. J. Pharmacol, 1999, 367, 197-206.
114. Arnsten, A.F. Stress impairs prefrontal cortical function in rats and monkeys: role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog. Brain Res.,2000, 126, 183-192.
115. Li, B.M.; Mei, Z.T. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav. Neural Biol., 1994, 62, 134-139.
116. Birnbaum, S.; Gobeske, K.T.; Auerbach, J.; Taylor, J.R.; Arnsten, A.F. A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol. Psychiatry, 1999, 46, 1266-1274.
117. A.F. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacol. (Berl), 2004, 174(1), 25-31.
118. Arnsten, A.F.; Contant, TA. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacol. (Berl), 1992,108, 159-169.
119. Arnsten, A.F.; Contant, TA. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J. Biol. Med., 2012, 85, 45-58.
120. Azmitia, E.C.; Segal, M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol, 1978, 179, 641-667.
121. Pazos, A.; Palacios, J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain I Serotonin-1 receptors. Brain Res., 1985, 346, 205-230.
122. Pazos, A.; Cortés, R.; Palacios, J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain II Serotonin-2 receptors. Brain Res., 1985, 346, 231-249.
123. Pompeiano, M.; Palacios, J.M.; Mengod, G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci., 1992, 12, 440-453.
124. Pompeiano, M.; Palacios, J.M.; Mengod, G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5HT2A and 5-HT2C receptors. Mol Brain Res., 1994, 23, 163-178.
125. López-Giménez, J.F.; Tecott, L.H.; Palacios, J.M.; Mengod, G.; Vilaró, M.T. Serotonin 5-HT2C receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J. Neurosci. Res., 2002, 67, 69-85.
126. Kia, H.K.; Miquel, M.C.; Brisorgueil, M.J.; Daval, G., Riad, M.; El Mestikawy, S., Hamon, M.; Vergé, D. Immunocytochemical localization of serotonin(1A) receptors in the rat central nervous system. J. Comp. Neurol, 1996, 365, 289-305.
127. Jakab, R.L.; Goldman-Rakic, P.S. 5-Hydroxytryptamine(2A) serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA, 1998, 95, 735-740.
128. Cornea-Hébert, V.; Riad, M.; Wu, C.; Singh, S.K.; Descarries L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol., 1999, 409, 187-209.
129. De Felipe, J.; Arellano, J.I.; Gomez, A.; Azmitia, E.C.; Munoz, A. Pyramidal cell axons show a local specialization for GABA and 5HT inputs in monkey and human cerebral cortex. J. Comp. Neurol., 2001, 433, 148-155.
130. Santana, N.; Bortolozzi, A.; Serrats, J.; Mengod, G.; Artigas, F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the prefrontal cortex. Cereb. Cortex, 2004, 14, 1100-1109.
131. Amargós-Bosch, M.; Bortolozzi, A.; Puig, V.; Serrats, J.; Adell, A.; Celada, P.; Toth, M.; Mengod, G.; Artigas, F. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb. Cortex, 2004, 14, 281-299.
132. Celada, P.; Artigas, F. Serotonergic modulation of cortical activity. In: Monoaminergic modulation of cortical excitability; Tseng K.Y.; Atzori M., Eds.; Spring: New York, 2007; pp. 197-207.
133. Puig, M.V.; Santana, N.; Celada, P.; Mengod, G.; Artigas, F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb. Cortex, 2004, 14, 1365-1375.
134. Díaz-Mataix, L.; Scorza, M.C.; Bortolozzi, A.; Toth, M.; Celada, P.; Artigas, F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci., 2005, 25, 10831-10843.
135. Díaz-Mataix, L.; Artigas, F.; Celada, P. Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist. Eur. Neuropsychopharmacol., 2006, 16, 288-296.
136. Lladó-Pelfort, L.; Santana, N.; Ghisi, V.; Artigas, F.; Celada, P. 5HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb. Cortex, 2012, 22, 1487-197.
137. Clarke, H.F.; Dalley, J.W.; Crofts, H.S.; Robbins, T.W.; Roberts A.C. Cognitive inflexibility after prefrontal serotonin depletion. Science, 2004, 304, 878-880.
138. Evers, E.A.; Cools, R.; Clark, L.; van der Veen, F.M.; Jolles, J.; Sahakian, B.J.; Robbins, T.W. Serotonergic modulation of prefrontal cortex during negative feedback in probabilistic reversal learning. Neuropsychopharmacology, 2005, 30, 1138-1147.
139. Williams, G.V.; Rao, S.G.; Goldman-Rakic, P.S. The physiological role of 5-HT2A receptors in working memory. J. Neurosci., 2002, 22, 2843-2854.
140. Nichols, D.E. Hallucinogens. Pharmacol. Ther., 2004, 101, 131181.
141. Jones, D.N.C.; Gartlon, J.E.; Minassian, A.; Perry, W.; Geyer, M.A. Developing new drugs for schizophrenia: from animals to the clinic. In: Animal and translational models for CNS drug discovery; McArthur, R.A.; Borsini, F. Eds; Academic Press: Amsterdam, 2008; Vol 1, pp. 199-261.
142. Benes, F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacol., 2001, 25, 1-27.
143. Lewis, D.A.; Gonzalez-Burgos, G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med., 2006, 12, 1016-1022.
144. Ford, J.M.; Krystal, J.H.; Mathalon, D.H. Neural synchrony in schizophrenia: from networks to new treatments. Schizophr. Bull., 2007, 33, 848-852.
145. Hoffman, D.C.; Donovan, H. D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology (Berl), 1994, 115, 447-453.
146. Swerdlow, N.R.; Shoemaker, J.M.; Bongiovanni, M.J.; Neary, A.C.; Tochen, L.S.; Saint Marie, R.L. Reduced startle gating after D1 blockade: effects of concurrent D2 blockade. Pharmacol. Biochem. Behav., 2005, 82, 293-299.
147. Karlsson, P.; Smith, L.; Farde, L.; Harnryd, C.; Sedvall, G.; Wiesel, F.A. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl), 1995, 121, 309-316.
148. Den Boer, J.A.; van Megen, H.J.; Fleischhacker W.W.; Louwerens, J.W.; Slaap, B.R.; Westenberg, H.G.; Burrows, G.D., Srivastava, O.N. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacol. (Berl), 1995, 121, 317-322.
149. Karle, J.; Clemmesen, L.; Hansen, L.; Andersen, M.; Andersen, J.; Fensbo, C.; Sloth-Nielsen, M., Skrumsager, B.K., Lublin, H.; Gerlach, J. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacol. (Berl), 1995, 121, 328-329.
150. Arnsten, A.F.; Cai, J.X.; Murphy, B.L.; Goldman-Rakic, P.S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacol. (Berl), 1994, 116, 143-151.
151. Cai, J.X., Arnsten, A.F. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J. Pharmacol. Exp. Ther., 1997, 283, 183-189.
152. Bubenikova-Valesova, V.; Svoboda, J.; Horacek, J.; Vales, K. The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpinetreated rats. Int. J. Neuropsychopharmacol., 2009, 12, 873-883.
153. George, M.S.; Molnar, C.E.; Grenesko, E.L.; Anderson, B.; Mu, Q.; Johnson, K.; Nahas, Z.; Knable, M.; Fernandes, P.; Juncos, J.; Huang, X.; Nichols, D.E.; Mailman, R.B. A single 20mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr. Res., 2007, 93: 42-50.
154. Benkert, O.; Muller-Siecheneder, F.; Wetzel, H. Dopamine agonists in schizophrenia: a review. Eur. Neuropsychopharmacol., 1995, 5, 43-53.
155. Newman-Tancredi, A.; Cussac, D.; Depoortere, R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs, 2007, 8, 539-554.
156. Semba, J.; Watanabe, A.; Kito, S.; Toru, M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropahrmacology, 1995, 34, 785-791.
157. Bortolozzi, A.; Díaz-Mataix, L.; Toth, M.; Celada, P.; Artigas, F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl), 2007, 191, 745-58.
158. Grunder, G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr. Opin. Investig. Drugs, 2010, 11, 823--832.
159. Kiss, B.; Horvath, A.; Nemethy, Z.; Schmidt, E.; Laszlovszky, I.; Bugovics, G.; Fazekas, K., Hornok, K., Orosz, S.; Gyertyán, I.; Agai-Csongor, E.; Domány, G.; Tihanyi, K., Adham, N.; Szombathelyi, Z. Cariprazine (RGH-188), a dopamine D(3) receptorpreferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther., 2010, 333, 328-340.
160. Schwartz, J.C.; Diaz, J.; Pilon, C.; Sokoloff, P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Rev., 2000, 31, 277-287.
161. Joyce, J.N.; Millan, M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today, 2005, 10, 917-925.
162. Remington, G.; Kapur, S. SB-277011 GlaxoSmithKline. Curr. Opin. Investig. Drugs, 2001, 2, 946-949.
163. Millan, M.J.; Brocco, M. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimized D(3) 4 D(2) antagonist, S33138. Therapie, 2008, 63, 187-229.
164. Watson, D.J.; Marsden, C.A.; Millan, M.J.; Fone, K.C. Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int. J. Neuropsychopharmacol., 2012, 15, 471-484.
165. Lahti, A.C.; Weiler, M.; Carlsson, A.; Tamminga, C.A. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)UH232 in schizophrenia. J. Neural. Transm., 1998, 105, 719-734.
166. Redden, L.; Rendenbach-Mueller, B.; Abi-Saab, W.M.; Katz, D.A.; Goenjian, A.; Robieson, W.Z. et al. A double-blind, randomized, placebo-controlled study of the dopamine.D3 receptor antagonist ABT-925 in patients with acute schizophrenia. J. Clin. Psychopharmacol., 2011, 31, 221-225.
167. Mrzljak, L.; Bergson, C.; Pappy, M.; Huff, R.; Levenson, R.; Goldman-Rakic, P.S. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature, 1996, 381, 245248.
168. Kramer, M.S.; Last, B.; Getson, A.; Reines, S.A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic in patients with schizophrenia. Arch. Gen. Psychiatry, 1997, 54, 567-572.
169. Truffinet, P.; Tamminga, C.A.; Fabre, L.F.; Meltzer, H.Y.; Riviere, M.E.; Papillon-Downey, C. Placebo-controlled study of the D4/5HT2A antagonist finanserin in the treatment of schizophrenia. Am. J. Psychiatry, 1999, 156, 419-425.
170. Corrigan, M.H.; Gallen, C.C.; Bonura, M.L.; Merchant, K.M. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol. Psychiatry, 2004, 55, 445-451.
171. Browman, K.E.; Curzon, P.; Pan, J.B.; Molesky, A.L.; Komater, V.A.; Decker, M.W.; Brioni, J.D.; Moreland, R.B.; Fox, G.B. A412997, a selective dopamine D4 agonist, improves cognitive performance in rats. Pharmacol. Biochem. Behav., 2005, 82, 148-155.
172. Bernaerts, P.; Tirelli, E. Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. Behav. Brain Res., 2003, 142, 41-52.
173. Millan, M. Improving the treatment os schizophrenia: focus on serotonin (5-HT)1A receptors. J. Pharmacol. Exp. Therap., 2000, 295, 853-861.
174. Rollema, H.; Lu, Y.; Schmidt, A.W.; Zorn, S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol., 1997, 338, R3-R5.
175. Kuroki, T.; Meltzer, H.Y.; Ichikawa, J. Effects of antipsychotics drugs on extracellualr dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther., 1999, 288, 774-781.
176. Rollema, H.; Lu, Y.; Schmidt, A.W.; Sprouse, J.S.; Zorn, S.H. 5HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry, 2000, 48, 229-237.
177. Bortolozzi, A.; Masana, M.; Díaz-Mataix, L.; Cortés, R.; Scorza, M.C.; Gingrich, J.A.; Toth, M.; Artigas, F. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5HT1A receptors but not 5-HT2A receptors. Int. J. Neuropsychopharmacol., 2010, 13, 1299-1314.
178. Lawler, C.P.; Prioleau, C.; Lewis, M.M. Mak, C.; Jiang, D.; Schetz, J.A.; Gonzalez, A.M.; Sibley, D.R.; Mailman, R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacol., 1999, 20, 612-627.
179. Newman-Tancredi, A.; Assié, M.B.; Leduc, N.; Ormière, A.M.; Danty, N.; Cosi, C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol., 2005, 8, 341-356.
180. Chou, Y.; Halldin, C. and Farde, L. Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacol., 2003, 166, 234-240.
181. Bantick, R.A.; Montgomery, A.J.; Bench, C.J.; Choudhry, T.; Malek, N.; McKenna, P.J.; Quested, D.J.; Deakin, J.F.; Grasby, P.M. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J. Psychopharmacol., 2004, 18, 346-354.
182. Ichikawa, J.; Ishii, H.; Bonaccorso, S.; Fowler, W.L.; O'Laughlin, I.A. and Meltzer, H.Y. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem., 2001, 76, 1521-1531.
183. Burnet, P.W.; Eastwood, S.L.; Harrison, P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacol., 1996, 15, 442455.
184. 3H]8-OHDPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biol. Psychiatry, 1996, 39, 919-928.
185. Sumiyoshi, T.; Matsui, M.; Nohara, S.; Yamashita, I.; Kurachi, M.; Sumiyoshi, C.; Jayathilake, K.; Meltzer, H.Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry, 2001, 158, 1722-1725.
186. Sumiyoshi, T.; Park, S.; Jayathilake, K.; Roy, A.; Ertugrul, A.; Meltzer, H.Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, doubleblind, placebo-controlled study. Schizophr. Res., 2007, 95, 158-168.
187. Newman-Tancredi, A.; Assié, M.B.; Martel, J.C.; Cosi, C.; Slot, L.B.; Palmier, C.; Rauly-Lestienne, I.; Colpaert, F.; Vacher, B.; Cussac, D. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile. Br. J. Pharmacol., 2007, 151, 237-252.
188. Jones, C.A.; McCreary, A.C. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacol., 2008, 55, 1056-1065.
189. Lladó-Pelfort, L.; Assié, M.B.; Newman-Tancredi, A.; Artigas, F.; Celada, P. Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors. Br. J. Pharmacol., 2010, 160, 1929-1940.
190. Depoortère, R.; Auclair, A.L., Bardin, L., Colpaert, F.C., Vacher, B.; Newman-Tancredi, A. F15599, a preferential post-synaptic 5HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur. Neuropsychopharmacol., 2010, 20, 641-654.
191. Rodriguez, J.J.; Garcia, D.R.; Pickel, V.M. Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum. J. Comp. Neurol., 1999, 413, 219-231.
192. O'Neill, M.F.; Heron-Maxwell, C.L.; Shaw, G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol. Biochem. Behav., 1999, 63, 237-243.
193. Lieberman, J.A.; Mailman, R.B.; Duncan, G.; Sikich, L.; Chakos, M.; Nichols, D.E.; Kraus, J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry, 1998, 44, 10991117.
194. Pehek, E.A.; McFarlane, H.G.; Maguschak, K.; Price, B.; Pluto, C.P. M100,907, a selective 5-HT2A antagonist attenuates dopamine release in the rat medial prefrontal cortex. Brain Res., 2001, 888, 51-59.
195. Bortolozzi, A.; Díaz-Mataix, L.; Scorza, M.C.; Celada, P.; Artigas, F. The activaction of 5-HT2A receptors enhances dopaminergic activity. J. Neurochem., 2005, 95, 1597-1607.
196. Vázquez-Borsetti, P.; Celada, P.; Cortés, R.; Artigas, F. Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei. Int. J. Neuropsychopharmacol., 2011, 14, 289-302.
197. Reynetjens, A.; Gelders, M.L.; Hoppenbrouwers, J.A.; Bussche, G.V. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev. Res., 1986, 8, 205-211.
198. Duinkerke, S.J.; Botter, P.A.; Jansen, A.A.; van Dongen, P.A.; van Haaften, A.J.; Boom, A.J.; van Laarhoven, J.H.; Busard, H.L. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry, 1993, 163, 451-455.
199. Akhondzadeh, S.; Malek-Hosseini, M.; Ghoreishi, A.; Raznahan, M.; Rezazadeh, S.A. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 1879-1883.
200. Carlsson, A. Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr. Opin. CPNS Invest. Drugs, 2000, 2, 2224.
201. Weiner, D.M.; Burstein, E.S.; Nash, N.; Croston, G.E.; Currier, E.A.; Vanover, K.E. et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther., 2001, 299, 268-276.
202. Abbas, A.; Roth, B.L. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert. Opin. Pharmacother., 2008, 9, 3251-3259.
203. Li, Z.; Ichikawa, J.; Huang, M.; Prus, A.J.; Dai, J.; Meltzer, H.Y. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidolinduced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacol. (Berl), 2005, 183, 144-53.
204. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharm. Biol. Psychiatry, 2003, 27, 1159-1172.
205. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J. Psychopharmacol, 2004, 18, 340-345.
206. Giorgetti, M.; Teccot, L.H. Contributions of 5-HT2C receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol., 2004, 488, 1-9.
207. Lucas, G.; Spampinato, U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem., 2000, 74, 693-701.
208. Prisco, S.; Pagannone, S.; Esposito, E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J. Pharmacol. Exp. Ther., 1994, 271, 83-90.
209. Millan, M.J.; Dekeyne, A.; Gobert, A. Serotonin 5-HT2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacol., 1998, 37, 953-955.
210. Di Matteo, V.; De Blasi, A.; Di Giulio, C.; Esposito, E. Role of 5HT2C receptors in the control of central dopamine function. Trends Pharmacol Sci., 2001, 22, 229-232.
211. Alex, K.D.; Pehek, E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther., 2007, 113, 296-320.
212. Siuciak, J.A.; Chapin, D.S.; McCarthy, S.A.; Guanowsky, V.; Brown, J.; Chiang, P.; Marala, R., Patterson, T.; Seymour, P.A.; Swick, A.; Iredale, P.A. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacol, 2007, 52, 279-290.
213. Kim, D.H.; Stahl, S.M. Antipsychotic drug development. Curr. Top. Behav. Neurosci., 2010, 4, 123-139.
214. Ramirez, M.J.; Cenarruzabeitia, E.; Lasheras, B.; Del Rio, J. Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex. Brain Res, 1996, 712, 274-280.
215. Imperato, A.; Angelucci, L. 5-HT3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neurosci. Lett., 1989, 101, 214-217.
216. Costall, B.; Naylor, R.J. 5-HT3 receptors. Curr. Drug Targets CNS Neurol. Disord., 2004, 3, 27-37.
217. Zhang, Z.J.; Kang, W.H.; Li, Q.; Wang, X.Y.; Yao, S.M.; Ma, A.Q. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res., 2006, 88, 102110.
218. Akhondzadeh, S.; Mohammadi, N.; Noroozian, M.; Karamghadiri, N.; Ghoreishi, A.; Jamshidi, A.H.; Forghani, S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr. Res., 2009, 107, 206-212.
219. Levkovitz, Y.; Arnest, G.; Mendlovic, S.; Treves, I.; Fennig, S. The effect of ondansetron on memory in schizophrenic patients. Brain Res. Bull., 2005, 65, 291-295.
220. Vilaró, M.T.; Cortés, R.; Gerald, C.; Branchek, T.A.; Palacios, J.M.; Mengod, G. Localization of 5-HT4 receptor mRNA in rat brain by in situ hybridization histochemistry. Brain Res. Mol. Brain Res., 1996, 43, 356-360.
221. Reynolds, G.P.; Mason, S.L.; Meldrum, A.; De Keczer, S.; Parnes, H., Eglen, R.M.; Wong, E.H. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol., 1995, 114, 993-998.
222. Roth, B.L; Hanizavareh, S.M; Blum, A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacol. (Berl), 2004, 174, 17-24.
223. Lamirault, L.; Guillou, C.; Thal, C.; Simon, H. Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 185-195.
224. Moser, P.C.; Bergis, O.E.; Jegham, S.; Lochead, A.; Duconseille, E.; Terranova, J.P.; Caille, D., Berque-Bestel, I.; Lezoualc'h, F.; Fischmeister, R.; Dumuis, A.; Bockaert, J.; George, P.; Soubrié, P.; Scatton, B. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J. Pharmacol. Exp. Ther., 2002, 302, 731-741.
225. Roth, B.L.; Craigo, S.C.; Choudhary, M.S.; Uluer, A.; Monsma, F.J.; Jr Shen, Y.; Meltzer, H.Y.; Sibley, D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther., 1994, 268, 1403-1410.
226. Bourson, A.; Borroni, E.; Austin, R.H.; Monsma, F.J. Jr.; Sleight, A.J. Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmacol. Exp. Ther., 1995, 274, 173-180.
227. Rogers, D.C.; Robinson, C.A.; Quilter, A.J.; Hunter, C.; Routledge, C.; Hagan, J.J. Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br. J. Pharmacol. Suppl., 1999, 127, 22.
228. Routledge, C.; Bromidge, S.M.; Moss, S.F.; Newman, H.; Riley, G.; Hagan, J.J. Characterization of SB-271046: a potent and selective 5-HT6 receptor antagonist. Br. J. Pharmacol. Suppl., 1999, 127, 21.
229. King, M.V.; Marsden, C.A.; Fone, K.C. A role for the 5-HT1A, 5HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol. Sci., 2008, 29, 482-492.
230. Rosse, G.; Schaffhauser, H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr. Top. Med. Chem., 2010, 10, 207-221.
231. Terry Jr., A.V.; Buccafusco, J.J.; Wilson, C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav. Brain Res., 2008, 195, 30-38.
232. Abbas, A.I.; Hedlund, P.B.; Huang, X.P.; Tran, T.B.; Meltzer, H.Y.; Roth, B.L. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacol. (Berl), 2009, 205, 119-128.
233. Pouzet, B.; Didriksen, M.; Arnt, J. Effects of the 5-HT7 receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol. Biochem. Behav., 2002, 71, 655-665.
234. Svensson, T.H. Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanism of action. Clinical Neuroscience Research, 2003, 3, 34-46
235. Amargós-Bosch, M.; Adell, A.; Bortolozzi, A.; Artigas, F. Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J. Neurochem., 2003, 87, 831-842.
236. Artigas, F. The prefrontal cortex: a target for antipsychotic drugs. Acta Psychiatr. Scand., 2010, 121, 11-21.
237. Wadenberg, M.L.; Hertel, P.; Fernholm, R.; Hygge Blakeman, K.; Ahlenius, S.; Svensson, T.H. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J. Neural Transm., 2000, 107, 12291238.
238. Friedman, J.I.; Adler, D.N.; Temporini, H.D.; Kemether, E.; Harvey, P.D.; White, L.; Parrella, M.; Davis, K.L. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacol., 2001, 25, 402-429.
239. Marrs, W.; Kuperman, J.; Avedian, T.; Roth, R.H.; Jentsch, J.D. Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacol, 2005, 30, 1500-1510.
240. Millan, M.; Gobert, A.; New-Tancredi, A.; Lejeune, F.; Cussac, D.; Rivet, J.M.; Audinot, V.; Adhumeau, A.; Brocco, M.; Nicolas, J.P.; Boutin, J.A.; Despaux, N.; Peglion, J.L. S18327, a novel, potential antipsychotic displaying marked antagonist properties at alpha1 and alpha2 adrenergic receptors: I. receptorial, neurochemical and electrophysiological profile. J. Pharmacol. Exp. Ther, 2000, 292, 38-53.
241. Litman, R.E.; Su, T.P.; Poter, W.Z.; Hong, W.W.; Pickar, D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry, 1996, 168, 571-579.
242. Wadenberg, M.L.; Wiker, C.; Svensson, T.H. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. Int. J. Neuropsychopharmacol., 2007, 10, 191-202.
243. Marcus, M.M.; Wiker, C.; Frånberg, O.; Konradsson-Geuken, A.; Langlois, X.; Jardemark, K.; Svensson, T.H. Adjunctive alpha2adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int. J. Neuropsychopharmacol., 2010, 13, 891-903.
244. Robbins, T.W.; Roberts, A.C. Differential regulation of frontoexecutive function by the monoamines and acetylcholine. Cereb. Cortex, 2007, 17, 151-160.
245. Sara, S.J. The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci., 2009, 10, 211-223.
246. Gresch, P.J.; Sved, A.F.; Zigmond, M.J.; Finlay, J.M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem., 1995, 65, 111-116.
247. Hertel, P.; Fagerquist, M.; Svensson, T. Enahcenced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science, 1999, 286, 105-107.
248. Linnér, L.; Wiker, C.; Wadenberg, M.L.; Schalling, M.; Svensson, T.H. Noradrenaline reuptake inhibition enhances the antipsychoticlike effect of raclopride and potentiates D2 blockage-induced dopamine release in the medial prefrontal cortex of rat. Neuropsychopharmacol., 2002, 27, 691-8.
249. Devoto, P.; Flore, G.; Pira, L.; Longu, G.; Gessa, G.L. Alpha2adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. J Neurochem., 2004, 88, 1003-1009.
250. Valentini, V.; Frau, R.; Di Chiara, G. Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J. Neurochem., 2004, 88, 917-927.
251. Masana, M.; Bortolozzi, A.; Artigas, F. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int. J. Neuropsychopharmacol., 2011, 14, 53-68.
252. Masana, M.; Castañé, A.; Santana, N.; Bortolozzi, A.; Artigas, F. Noradrenergic antidepressants increase cortical dopamine: Potential use in augmentation strategies. Neuropharmacology, 2012, 63, 675-684.
253. Marcus, M.M.; Jardemark, K.; Malmerfelt, A.; Björkholm, C.; Svensson, T.H. Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. Neuropsychopharmacol., 2010, 35, 1952-1961.
254. Schutz, G.; Berk, M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebocontrolled study. Int. Clin. Psychopharmacol., 2001, 16, 275278.
255. Raedler, T.J.; Jahn, H.; Arlt, J.; Kiefer, F.; Schick, M.; Naber, D.; Wiedemann, K. Adjunctive use of reboxetine in schizophrenia. Eur. Psychiatry, 2004, 19, 366-369.
256. Friedman, J.I.; Carpenter, D.; Lu, J.; Fan, J.; Tang, C.Y.; White, L.; Parrella, M.; Bowler, S.; Elbaz, Z.; Flanagan, L.; Harvey, P.D. A pilot study of adjunctive atomoxetine treatment to secondgeneration antipsychotics for cognitive impairment in schizophrenia. J. Clin. Psychopharmacol., 2008, 28, 59-63.
257. Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L.; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.; Gurovich, I.Y.; Morozova, M.A.; Mosolov, S.N.; Neznanov, N.G.; Reznik, A.M.; Smulevich, A.B.; Tochilov, V.A.; Johnson, B.G.; Monn, J.A.; Schoepp, D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med., 2007, 13, 1102-1107.
258. Ross, C.A.; Margolis, R.L.; Reading, S.A.; Pletnikov, M.; Coyle, J.T. Neurobiology of schizophrenia. Neuron, 2006, 52, 139-153.
259. Thome, J.; Foley, P.; Riederer, P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. J. Neural. Transm., 1998, 105, 85-100.
260. Stahl, S.M. When neurotrophic factors get on your nerves: therapy for neurodegenerative disorders. J. Clin. Psychiatry, 1998, 59, 277-278.
261. Menniti, F.S.; Chappie, T.A.; Humphrey, J.M.; Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr. Opin. Investig. Drugs, 2007, 8, 54-59.